Cargando…
Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized Clinical Phase III Trial
INTRODUCTION: Poor prognosis patients with bulky stage III locally advanced non–small-cell lung cancer may not be offered concurrent chemoradiotherapy (CRT). Following a phase III trial concerning the effect of palliative CRT in inoperable poor prognosis patients, this analysis was performed to expl...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132042/ https://www.ncbi.nlm.nih.gov/pubmed/24807158 http://dx.doi.org/10.1097/JTO.0000000000000184 |
_version_ | 1782330557488693248 |
---|---|
author | Strøm, Hans H. Bremnes, Roy M. Sundstrøm, Stein H. Helbekkmo, Nina Aasebø, Ulf |
author_facet | Strøm, Hans H. Bremnes, Roy M. Sundstrøm, Stein H. Helbekkmo, Nina Aasebø, Ulf |
author_sort | Strøm, Hans H. |
collection | PubMed |
description | INTRODUCTION: Poor prognosis patients with bulky stage III locally advanced non–small-cell lung cancer may not be offered concurrent chemoradiotherapy (CRT). Following a phase III trial concerning the effect of palliative CRT in inoperable poor prognosis patients, this analysis was performed to explore how tumor size influenced survival and health-related quality of life (HRQOL). METHODS: A total of 188 poor prognosis patients recruited in a randomized clinical trial received four courses intravenous carboplatin day 1 and oral vinorelbine day 1 and 8, at 3-week intervals. The experimental arm (N = 94) received radiotherapy with fractionation 42 Gy/15, starting at the second chemotherapy course. This subset study compares outcomes in patients with tumors larger than 7 cm (N = 108) versus tumors 7 cm or smaller (N = 76). RESULTS: Among those with tumors larger than 7 cm, the median overall survival in the chemotherapy versus CRT arm was 9.7 and 13.4 months, respectively (p = 0.001). The 1-year survival was 33% and 56%, respectively (p = 0.01). Except for a temporary decline during treatment, HRQOL was maintained in the CRT arm, regardless of tumor size. Among those who did not receive CRT, patients with tumors larger than 7 cm experienced a gradual decline in the HRQOL. The CRT group had significantly more esophagitis and hospitalizations because of side effects regardless of tumor size. CONCLUSION: In patients with poor prognosis and inoperable locally advanced non–small-cell lung cancer, large tumor size should not be considered a negative predictive factor. Except for performance status 2, patients with tumors larger than 7 cm apparently benefit from CRT. |
format | Online Article Text |
id | pubmed-4132042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-41320422014-08-14 Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized Clinical Phase III Trial Strøm, Hans H. Bremnes, Roy M. Sundstrøm, Stein H. Helbekkmo, Nina Aasebø, Ulf J Thorac Oncol Original Articles INTRODUCTION: Poor prognosis patients with bulky stage III locally advanced non–small-cell lung cancer may not be offered concurrent chemoradiotherapy (CRT). Following a phase III trial concerning the effect of palliative CRT in inoperable poor prognosis patients, this analysis was performed to explore how tumor size influenced survival and health-related quality of life (HRQOL). METHODS: A total of 188 poor prognosis patients recruited in a randomized clinical trial received four courses intravenous carboplatin day 1 and oral vinorelbine day 1 and 8, at 3-week intervals. The experimental arm (N = 94) received radiotherapy with fractionation 42 Gy/15, starting at the second chemotherapy course. This subset study compares outcomes in patients with tumors larger than 7 cm (N = 108) versus tumors 7 cm or smaller (N = 76). RESULTS: Among those with tumors larger than 7 cm, the median overall survival in the chemotherapy versus CRT arm was 9.7 and 13.4 months, respectively (p = 0.001). The 1-year survival was 33% and 56%, respectively (p = 0.01). Except for a temporary decline during treatment, HRQOL was maintained in the CRT arm, regardless of tumor size. Among those who did not receive CRT, patients with tumors larger than 7 cm experienced a gradual decline in the HRQOL. The CRT group had significantly more esophagitis and hospitalizations because of side effects regardless of tumor size. CONCLUSION: In patients with poor prognosis and inoperable locally advanced non–small-cell lung cancer, large tumor size should not be considered a negative predictive factor. Except for performance status 2, patients with tumors larger than 7 cm apparently benefit from CRT. Lippincott Williams & Wilkins 2014-06 2014-05-30 /pmc/articles/PMC4132042/ /pubmed/24807158 http://dx.doi.org/10.1097/JTO.0000000000000184 Text en Copyright © 2014 by the International Association for the Study of Lung Cancer This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Original Articles Strøm, Hans H. Bremnes, Roy M. Sundstrøm, Stein H. Helbekkmo, Nina Aasebø, Ulf Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized Clinical Phase III Trial |
title | Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized Clinical Phase III Trial |
title_full | Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized Clinical Phase III Trial |
title_fullStr | Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized Clinical Phase III Trial |
title_full_unstemmed | Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized Clinical Phase III Trial |
title_short | Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized Clinical Phase III Trial |
title_sort | poor prognosis patients with inoperable locally advanced nsclc and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase iii trial |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132042/ https://www.ncbi.nlm.nih.gov/pubmed/24807158 http://dx.doi.org/10.1097/JTO.0000000000000184 |
work_keys_str_mv | AT strømhansh poorprognosispatientswithinoperablelocallyadvancednsclcandlargetumorsbenefitfrompalliativechemoradiotherapyasubsetanalysisfromarandomizedclinicalphaseiiitrial AT bremnesroym poorprognosispatientswithinoperablelocallyadvancednsclcandlargetumorsbenefitfrompalliativechemoradiotherapyasubsetanalysisfromarandomizedclinicalphaseiiitrial AT sundstrømsteinh poorprognosispatientswithinoperablelocallyadvancednsclcandlargetumorsbenefitfrompalliativechemoradiotherapyasubsetanalysisfromarandomizedclinicalphaseiiitrial AT helbekkmonina poorprognosispatientswithinoperablelocallyadvancednsclcandlargetumorsbenefitfrompalliativechemoradiotherapyasubsetanalysisfromarandomizedclinicalphaseiiitrial AT aasebøulf poorprognosispatientswithinoperablelocallyadvancednsclcandlargetumorsbenefitfrompalliativechemoradiotherapyasubsetanalysisfromarandomizedclinicalphaseiiitrial |